Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 7Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia 3Hodgkin Disease 3Melanoma 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Rituximab 40Cyclophosphamide 29Etoposide 15Doxorubicin 14Vincristine 13Prednisone 13ibrutinib 10fludarabine 10fludarabine phosphate 8Cytarabine 8Mycophenolic Acid 7Bortezomib 7Lenalidomide 6Carmustine 6pembrolizumab 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Inotuzumab Ozogamicin 5Whole-Body Irradiation 4Tacrolimus 4Carboplatin 4CT-P10 4Brentuximab Vedotin 4Antilymphocyte Serum 4tositumomab I-131 3tocilizumab 3tazemetostat 3obinutuzumab 3idelalisib 3etoposide phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell × Blood Component Removal × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡